A systems biology approach to antimalarial drug discovery

References

• Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361(5):455–467.
   PubMed Web of Science ®Google Scholar
• Geiling EK, Cannon PR. Pathologic effects of elixir of sulfanilamide (diethylene glycol) poisoning: a clinical and experimental correlation: final report. J Amer Med Ass. 1938;111(10):919–926.
   Google Scholar
• Bartlett JB, Dredge K, Dalgleish AG. Timeline the evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Canc. 2004;4(4):314–322.
   PubMed Web of Science ®Google Scholar
• Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today. 2015;105(2):140–156.
   PubMedGoogle Scholar
• Berman AY, Motechin RA, Wiesenfeld MY, et al. The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol. 2017;35(1).
   Web of Science ®Google Scholar
• Das S, Lo AW. Re-inventing drug development: a case study of the I-SPY 2 breast cancer clinical trials program. Contemp Clin Trials. 2017;62:168–174.
   PubMed Web of Science ®Google Scholar
• Garcia-Canaveras JC, Castell JV, Donato MT, et al. metabolomics cell-based approach for anticipating and investigating drug-induced liver injury. Sci Rep. 2016;6:27239.
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. Common pitfalls in preclinical cancer target validation. Nat Rev Cancer. 2017;17(7):425–440.
   PubMed Web of Science ®Google Scholar
• Brazma A, Krestyaninova M, Sarkans U. Standards for systems biology. Nat Rev Genet. 2006;7(8):593–605.
   PubMed Web of Science ®Google Scholar
• Cassman M. Barriers to progress in systems biology. Nature. 2005;438(7071):1079.
   PubMed Web of Science ®Google Scholar
• Winzeler EA. Applied systems biology and malaria. Nat Rev Microbiol. 2006;4(2):145–151.
   PubMed Web of Science ®Google Scholar
• Kazmin D, Nakaya HI, Lee EK, et al. Systems analysis of protective immune responses to RTS,S malaria vaccination in humans. Proc Natl Acad Sci U S A. 2017;114(9):2425–2430.
   PubMed Web of Science ®Google Scholar
• Brodland GW. How computational models can help unlock biological systems. Semin Cell Dev Biol. 2015;47–48:62–73.
   PubMed Web of Science ®Google Scholar
• Nussinov R. Advancements and challenges in computational biology. PLoS Comput Biol. 2015;11(1):e1004053.
   PubMed Web of Science ®Google Scholar
• Noble D. Computational models of the heart and their use in assessing the actions of drugs. J Pharmacol Sci. 2008;107(2):107–117.
   PubMed Web of Science ®Google Scholar
• Schoeberl B, Kudla A, Masson K, et al. Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121). NPJ Syst Biol Appl. 2017;3:16034.
   PubMed Web of Science ®Google Scholar
• Van Voorhis WC, Adams JH, Adelfio R, et al. Open source drug discovery with the malaria box compound collection for neglected diseases and beyond. PLoS Pathog. 2016;12(7):e1005763.
   PubMed Web of Science ®Google Scholar
• Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest. 2007;117(4):850–858.
   PubMed Web of Science ®Google Scholar
• White NJ. Plasmodium knowlesi: the fifth human malaria parasite. Clin Infect Dis. 2008;46(2):172–173.
   PubMed Web of Science ®Google Scholar
• World malaria report 2015. World Health Organisation: Geneva, 2015. Available from: http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/. [cited 2018 April 14].
   Google Scholar
• Insecticide resistance. Available from: http://www.who.int/malaria/areas/vector_control/insecticide_resistance/en/. [cited 2018 March 26].
   Google Scholar
• Amino R, Thiberge S, Martin B, et al. Quantitative imaging of Plasmodium transmission from mosquito to mammal. Nat Med. 2006;12(2):220–224.
   PubMed Web of Science ®Google Scholar
• Amino R, Giovannini D, Thiberge S, et al. Host cell traversal is important for progression of the malaria parasite through the dermis to the liver. Cell Host Microbe. 2008;3(2):88–96.
   PubMed Web of Science ®Google Scholar
• Miller LH, Ackerman HC, Su XZ, et al. Malaria biology and disease pathogenesis: insights for new treatments. Nat Med. 2013;19(2):156–167.
   PubMed Web of Science ®Google Scholar
• Menard R, Tavares J, Cockburn I, et al. Looking under the skin: the first steps in malarial infection and immunity. Nat Rev Microbiol. 2013;11(10):701–712.
   PubMed Web of Science ®Google Scholar
• Hanboonkunupakarn B, White NJ. The threat of antimalarial drug resistance. Trop Dis Trav Med Vac. 2016;2(1):10.
   PubMedGoogle Scholar
• Peters W. Plasmodium: resistance to antimalarial drugs. Ann Parasitol Hum Comp. 1990;65(Suppl 1):103–106.
   PubMedGoogle Scholar
• Price RN, Uhlemann AC, Brockman A, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004;364(9432):438–447.
   PubMed Web of Science ®Google Scholar
• Foley M, Tilley L. Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. Pharmacol Ther. 1998;79(1):55–87.
   PubMed Web of Science ®Google Scholar
• Cortopassi WA, Oliveira AA, Guimaraes AP, et al. Docking studies on the binding of quinoline derivatives and hematin to Plasmodium falciparum lactate dehydrogenase. J Biomol Struct Dyn. 2011;29(1):207–218.
   PubMed Web of Science ®Google Scholar
• Read JA, Wilkinson KW, Tranter R, et al. Chloroquine binds in the cofactor binding site of Plasmodium falciparum lactate dehydrogenase. J Biol Chem. 1999;274(15):10213–10218.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang CJ, Chia WN, et al. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat Commun. 2015;6:10111.
   PubMed Web of Science ®Google Scholar
• Wong YK, Xu CC, Kalesh KA, et al. Artemisinin as an anticancer drug: recent advances in target profiling and mechanisms of action. Med Res Rev. 2017;37(6):1492–1517.
   PubMed Web of Science ®Google Scholar
• Kavishe RA, Koenderink JB, Alifrangis M. Oxidative stress in malaria and artemisinin combination therapy: pros and Cons. Febs J. 2017;284(16):2579–2591.
   PubMed Web of Science ®Google Scholar
• Cui L, Su XZ. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther. 2009;7(8):999–1013.
   PubMed Web of Science ®Google Scholar
• Achan J, Talisuna AO, Erhart A, et al. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J. 2011;10:144.
   PubMed Web of Science ®Google Scholar
• Thu AM, Phyo AP, Landier J, et al. Combating multidrug-resistant Plasmodium falciparum malaria. Febs J. 2017;284(16):2569–2578.
   PubMed Web of Science ®Google Scholar
• Zaw MT, Emran NA, Lin Z. Updates on k13 mutant alleles for artemisinin resistance in Plasmodium falciparum. J Microbiol Immunol Infect. 2017;51(2):159-165.
   Google Scholar
• Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg. 2007;77(6 Suppl):181–192.
   PubMed Web of Science ®Google Scholar
• Aguiar AC, De Sousa LRF, Garcia CRS, et al. New molecular targets and strategies for antimalarial discovery. Curr Med Chem. 2017;24. doi: 10.2174/0929867324666170830103003
   PubMedGoogle Scholar
• Bechtsi DP, Waters AP. Genomics and epigenetics of sexual commitment in Plasmodium. Int J Parasitol. 2017;47(7):425–434.
   PubMed Web of Science ®Google Scholar
• Creek DJ, Chua HH, Cobbold SA, et al. Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action. Antimicrob Agents Ch. 2016;60(11):6650–6663.
   PubMed Web of Science ®Google Scholar
• Hovlid ML, Winzeler EA. Phenotypic screens in antimalarial drug discovery. Trends Parasitol. 2016;32(9):697–707.
   PubMed Web of Science ®Google Scholar
• Horak P, Frohling S, Glimm H. Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. ESMO Open. 2016;1(5):e000094.
   PubMed Web of Science ®Google Scholar
• Wooller SK, Benstead-Hume G, Chen X, et al. Bioinformatics in translational drug discovery. Biosci Rep. 2017;37:4.
   Web of Science ®Google Scholar
• Gardner MJ, Hall N, Fung E, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 2002;419(6906):498–511.
   PubMed Web of Science ®Google Scholar
• Bruggeman FJ, Westerhoff HV. The nature of systems biology. Trends Microbiol. 2007;15(1):45–50.
   PubMed Web of Science ®Google Scholar
• Jamal S, Periwal V. Open source drug discovery, c.; scaria, v., predictive modeling of anti-malarial molecules inhibiting apicoplast formation. BMC Bioinformatics. 2013;14:55.
   PubMed Web of Science ®Google Scholar
• Pradhan A, Siwo GH, Singh N, et al. Chemogenomic profiling of Plasmodium falciparum as a tool to aid antimalarial drug discovery. Sci Rep. 2015;5:15930.
   Google Scholar
• Spitzmuller A, Mestres J. Prediction of the P. falciparum target space relevant to malaria drug discovery. PLoS Comput Biol. 2013;9(10):e1003257.
   PubMed Web of Science ®Google Scholar
• Bento AP, Gaulton A, Hersey A, et al. The ChEMBL bioactivity database: an update. Nucleic Acids Res. 2014;42(Database issue):D1083–90.
   PubMed Web of Science ®Google Scholar
• Slater HC, Okell LC, Ghani AC. Mathematical modelling to guide drug development for malaria elimination. Trends Parasitol. 2017;33(3):175–184.
   PubMed Web of Science ®Google Scholar
• Penna-Coutinho J, Almela MJ, Miguel-Blanco C, et al. Transmission-blocking potential of mefas, a hybrid compound derived from artesunate and mefloquine. Antimicrob Agents Chemother. 2016;60(5):3145–3147.
   PubMed Web of Science ®Google Scholar
• De Pilla Varotti F, Botelho AC, Andrade AA, et al. Synthesis, antimalarial activity, and intracellular targets of MEFAS, a new hybrid compound derived from mefloquine and artesunate. Antimicrob Agents Chemother. 2008;52(11):3868–3874.
   PubMed Web of Science ®Google Scholar
• Slater HC, Walker PG, Bousema T, et al. The potential impact of adding ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study. J Infect Dis. 2014;210(12):1972–1980.
   PubMed Web of Science ®Google Scholar
• Ogbunugafor CB, Wylie CS, Diakite I, et al. Adaptive landscape by environment interactions dictate evolutionary dynamics in models of drug resistance. PLoS Comput Biol. 2016;12(1):e1004710.
   Web of Science ®Google Scholar
• Coteron JM, Marco M, Esquivias J, et al. Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. J Med Chem. 2011;54(15):5540–5561.
   PubMed Web of Science ®Google Scholar
• McCarthy JS, Lotharius J, Ruckle T, et al. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. Lancet Infect Dis. 2017;17(6):626–635.
   PubMed Web of Science ®Google Scholar
• Rottmann M, McNamara C, Yeung BK, et al. Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010;329(5996):1175–1180.
   PubMed Web of Science ®Google Scholar
• Wells TN, Van Huijsduijnen RH, Van Voorhis WC. Malaria medicines: a glass half full? Nat Rev Drug Discov. 2015;14(6):424–442.
   PubMed Web of Science ®Google Scholar
• Jimenez-Diaz MB, Ebert D, Salinas Y, et al. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium (vol 111, pg E5455, 2014). P Natl Acad Sci USA. 2015;112(42):E5764–E5764.
   PubMed Web of Science ®Google Scholar
• Younis Y, Douelle F, Feng TS, et al. 3,5-diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J Med Chem. 2012;55(7):3479–3487.
   PubMed Web of Science ®Google Scholar
• Paquet T, Le Manach C, Cabrera DG, et al. Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. Sci Transl Med. 2017; 9(387) doi: 10.1126/scitranslmed.aad9735.
   PubMed Web of Science ®Google Scholar
• Baart GJ, Martens DE. Genome-scale metabolic models: reconstruction and analysis. Methods Mol Biol. 2012;799:107–126.
   PubMedGoogle Scholar
• Reed JL, Vo TD, Schilling CH, et al. An expanded genome-scale model of Escherichia coli K-12 (iJR904 GSM/GPR). Genome Biol. 2003;4(9):R54.
   PubMed Web of Science ®Google Scholar
• Edwards JS, Palsson BO. The Escherichia coli MG1655 in silico metabolic genotype: its definition, characteristics, and capabilities. Proc Natl Acad Sci U S A. 2000;97(10):5528–5533.
   PubMed Web of Science ®Google Scholar
• Plata G, Hsiao TL, Olszewski KL, et al. Reconstruction and flux-balance analysis of the Plasmodium falciparum metabolic network. Mol Syst Biol. 2010;6:408.
   PubMed Web of Science ®Google Scholar
• Huthmacher C, Hoppe A, Bulik S, et al. Antimalarial drug targets in Plasmodium falciparum predicted by stage-specific metabolic network analysis. BMC Syst Biol. 2010;4:120.
   PubMed Web of Science ®Google Scholar
• Orth JD, Thiele I, Palsson BO. What is flux balance analysis? Nat Biotechnol. 2010;28(3):245–248.
   PubMed Web of Science ®Google Scholar
• Chiappino-Pepe A, Tymoshenko S, Ataman M, et al. Bioenergetics-based modeling of Plasmodium falciparum metabolism reveals its essential genes, nutritional requirements, and thermodynamic bottlenecks. PLoS Comput Biol. 2017;13(3):e1005397.
   PubMed Web of Science ®Google Scholar
• Kirchner S, Power BJ, Waters AP. Recent advances in malaria genomics and epigenomics. Genome Med. 2016;8(1):92.
   PubMedGoogle Scholar
• Cortopassi WA, Kumar K, Duarte F, et al. Mechanisms of histone lysine-modifying enzymes: a computational perspective on the role of the protein environment. J Mol Graph Model. 2016;67:69–84.
   PubMed Web of Science ®Google Scholar
• Doerig C, Rayner JC, Scherf A, et al. Post-translational protein modifications in malaria parasites. Nat Rev Microbiol. 2015;13(3):160–172.
   PubMed Web of Science ®Google Scholar
• Freitas-Junior LH, Hernandez-Rivas R, Ralph SA, et al. Telomeric heterochromatin propagation and histone acetylation control mutually exclusive expression of antigenic variation genes in malaria parasites. Cell. 2005;121(1):25–36.
   PubMed Web of Science ®Google Scholar
• Lopez-Rubio JJ, Gontijo AM, Nunes MC, et al. 5ʹ flanking region of var genes nucleate histone modification patterns linked to phenotypic inheritance of virulence traits in malaria parasites. Mol Microbiol. 2007;66(6):1296–1305.
   PubMed Web of Science ®Google Scholar
• Chookajorn T, Dzikowski R, Frank M, et al. Epigenetic memory at malaria virulence genes. Proc Natl Acad Sci U S A. 2007;104(3):899–902.
   PubMed Web of Science ®Google Scholar
• Tonkin CJ, Carret CK, Duraisingh MT, et al. Sir2 paralogues cooperate to regulate virulence genes and antigenic variation in Plasmodium falciparum. PLoS Biol. 2009;7(4):e84.
   PubMed Web of Science ®Google Scholar
• Brancucci NM, Bertschi NL, Zhu L, et al. Heterochromatin protein 1 secures survival and transmission of malaria parasites. Cell Host Microbe. 2014;16(2):165–176.
   PubMed Web of Science ®Google Scholar
• Bartfai R, Hoeijmakers WA, Salcedo-Amaya AM, et al. H2A.Z demarcates intergenic regions of the Plasmodium falciparum epigenome that are dynamically marked by H3K9ac and H3K4me3. PLoS Pathog. 2010;6(12):e1001223.
   PubMed Web of Science ®Google Scholar
• Chaal BK, Gupta AP, Wastuwidyaningtyas BD, et al. Histone deacetylases play a major role in the transcriptional regulation of the Plasmodium falciparum life cycle. PLoS Pathog. 2010;6(1):e1000737.
   PubMed Web of Science ®Google Scholar
• Cui L, Miao J, Cui L. Cytotoxic effect of curcumin on malaria parasite Plasmodium falciparum: inhibition of histone acetylation and generation of reactive oxygen species. Antimicrob Agents Chemother. 2007;51(2):488–494.
   PubMed Web of Science ®Google Scholar
• Balasubramanyam K, Varier RA, Altaf M, et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem. 2004;279(49):51163–51171.
   PubMed Web of Science ®Google Scholar
• White NJ. Antimalarial drug resistance. J Clin Invest. 2004;113(8):1084-92.
   Web of Science ®Google Scholar
• Malaria Genomic Epidemiology Network (multiple authors). A global network for investigating the genomic epidemiology of malaria. Nature. 2008;456(7223):732–737.
   PubMed Web of Science ®Google Scholar
• MalariaGEN Plasmodium falciparum Community Project (multiple authors). Genomic epidemiology of artemisinin resistant malaria. Elife. 2016;5:e08714.
   Web of Science ®Google Scholar
• Sibley CH, Barnes KI, Plowe CV. The rationale and plan for creating a World Antimalarial Resistance Network (WARN). Malar J. 2007;6:118.
   PubMed Web of Science ®Google Scholar
• Plowe CV, Roper C, Barnwell JW, et al. World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J. 2007;6:121.
   PubMed Web of Science ®Google Scholar
• Tun KM, Imwong M, Lwin KM, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015;15(4):415-21.
   Web of Science ®Google Scholar